RxDoctor Payments DataLook up a doctor →

Todd Furness, DO

General Practice · Draper, UTNPI 1285941310

Payments from drug & device makers

$7,857in general payments, 2019–2025

Across 493 payments — averaging $15.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$820
  • Astellas Pharma US Inc$659
  • Lilly USA, LLC$479
  • Boston Scientific$401
  • Boehringer Ingelheim$399
  • plus $4K from 47 others

What the payments were for

  • Food & beverage$7,75799%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,857 in reported general payments places this provider in the 95th percentile of 1,070 general practice providers in Utah.

See all general practice providers in Utah

Medicare billing

Part B allowed, 2024
$75,972
Medicare patients
200
Services billed
975

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide126$157,338
FarxigaDapagliflozin Propanediol85$90,076
JardianceEmpagliflozin41$58,920
EliquisApixaban54$54,927
Tresiba Flextouch U-200Insulin Degludec31$49,925
TrulicityDulaglutide32$43,516
Soliqua 100-33Insulin Glargine/Lixisenatide27$42,420
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$37,536
RybelsusSemaglutide24$34,624
MounjaroTirzepatide25$31,608
Xultophy 100-3.6Insulin Degludec/Liraglutide12$30,389
GemtesaVibegron27$21,402
XareltoRivaroxaban21$21,292
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$20,621
VraylarCariprazine Hcl11$16,576

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6$379$222,350162 claims
AstraZenecaFarxiga, Symbicort$344$94,27497 claims
Lilly USA, LLCTrulicity, Mounjaro$479$75,12457 claims
Boehringer IngelheimJardiance, Spiriva Respimat$399$73,36759 claims
PfizerEliquis$301$54,92754 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$251$42,42027 claims
GSKTrelegy Ellipta$395$37,53636 claims
Sumitomo Pharma America, Inc.Gemtesa$40$21,40227 claims
Johnson & JohnsonXarelto$173$21,29221 claims
AbbVieVraylar$1,022$16,57611 claims
BayerKerendia$119$16,11511 claims
MerckBelsomra$139$6,05112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,070 general practice providers in Utah.

Other general practice in Draper

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →